BioCryst Announces RAPIVAB (peramivir injection) and Galidesivir Presentations at IDWeek 2017


BioCryst Pharmaceuticals, Inc. announced today that interim results from a clinical trial of a single IV dose of RAPIVABA for the treatment of pediatric influenza and results from preclinical studies of galidesivir in Rhesus macaques models of Zika virus infection and Ebola virus infection will be presented at IDWeek 2017 a , taking place in San Diego, October 4-8, 2017. Results from a pediatric clinical trial of RAPIVABA will be presented in two poster sessions.



from Biotech News